0000899243-16-019213.txt : 20160504 0000899243-16-019213.hdr.sgml : 20160504 20160504170637 ACCESSION NUMBER: 0000899243-16-019213 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160502 FILED AS OF DATE: 20160504 DATE AS OF CHANGE: 20160504 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 440 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 440 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pomerantz Roger CENTRAL INDEX KEY: 0001614936 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 161620379 MAIL ADDRESS: STREET 1: 711 HARVEST HILL ROAD CITY: CHALFONT STATE: PA ZIP: 18914 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-05-02 0 0001609809 Seres Therapeutics, Inc. MCRB 0001614936 Pomerantz Roger C/O SERES THERAPEUTICS, INC. 215 FIRST STREET CAMBRIDGE MA 02142 1 1 0 0 President and CEO Common Stock 2016-05-02 4 M 0 43687 0.71 A 66414 D Common Stock 2016-05-02 4 S 0 35438 28.95 D 30976 D Common Stock 2016-05-02 4 S 0 8249 29.59 D 22727 D Common Stock 2016-05-03 4 M 0 23680 0.71 A 46407 D Common Stock 2016-05-03 4 S 0 16338 27.80 D 30069 D Common Stock 2016-05-03 4 S 0 7142 28.44 D 22927 D Common Stock 2016-05-03 4 S 0 200 29.32 D 22727 D Stock Option (right to buy) 0.71 2016-05-02 4 M 0 43687 0.00 D 2024-08-07 Common Stock 43687 1624564 D Stock Option (right to buy) 0.71 2016-05-03 4 M 0 23680 0.00 D 2024-08-07 Common Stock 23680 1600884 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on February 26, 2016. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.39 to $29.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.395 to $30.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $27.2 to $28.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.21 to $29.16. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 25% of the shares subject to the option on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. /s/ Eric Shaff Attorney-in-fact 2016-05-04